Eli Lilly & Co.: Big Pharma Checkup for 2014

The patent cliff hits Eli Lilly (LLY) hard in 2014. Here's how Lilly hopes to survive the sales headwind and compete against AstraZeneca (AZN), Novo Nordisk (NVO) and Sanofi (SNY)

Jan 9, 2014 at 6:30PM

Few big pharma companies face as many challenges as Eli Lilly (NYSE:LLY) does this year. The company's blockbuster antidepressant drug Cymbalta, which generated sales of $4 billion in 2012 faces generic competition for the first time this year. And another $1 billion in sales goes up for grabs when Lilly's Evista loses patent protection in March.

Those high profile expirations will mean Lilly will have to rely more on its diabetes drugs and cost cutting to protect earnings this year. However stiff competition from diabetes drug makers AstraZeneca, (NYSE:AZN) Novo Nordisk, (NYSE:NVO) and Sanofi (NYSE:SNY) means there will plenty of obstacles to overcome for Lilly in 2014.

Competing for billions in the expanding diabetes market

Lilly is a long standing maker of insulin and related products for diabetes patients. Its Humalog is the company's third best selling drug and given that a larger, longer-living population is likely to significantly increase the global diabetes population beyond the 347 million currently diagnosed, the market opportunity is big.

But Lilly will have its hands full competing against other diabetes heavy-weights including AstraZeneca, Novo, and Sanofi. Projections peg the diabetes market opportunity will climb from $113 billion to $336 billion in the U.S. over the next 20 years alone and that has all four companies angling pipelines toward new treatments.

Just this past week AstraZeneca won approval for its new SGLT-2 class drug for type 2 diabetes. Analysts think Farxiga, also known by its generic name dapagliflozin, could eventually reach peak sales of up to $1.5 billion by 2018. Farxiga joins Astra's other diabetes drugs Onglyza, Kombiglyze, and Byetta, as part of a robust franchise that was created by Astra's acquisition in December of the half of its diabetes partnership that was previously owned by Bristol-Myers.

Novo has six drugs filed or in phase 3 trials for diabetes that it hopes will solidify its 27% market share in diabetes treatment. The company's synthetic insulin continues to win business globally and despite being dealt a blow in early 2013 when the FDA opted against its Tresiba, Novo thinks it has plenty of opportunity to build upon the success of its market leading GLP-1 diabetes drug Victoza.

Sanofi is vying for a share of Victoza's GLP-1 business with Lyxumia, which its selling in Europe. The company announced in September its slowing its pace toward an FDA filing for approval while it waits for additional phase 3 data. If that data is strong, Lyxumia would complement Sanofi's blockbuster diabetes drug Lantus, which had sales of $638 million during the third quarter.

Surviving its transition year

All four of the competitors are profitable, with Novo boasting the best operating margins at 38%. Lilly's margin has stabilized from its late 2012 lows and climbed to 27% in the third quarter thanks to pricing and cost cutting.

LLY Operating Margin (TTM) Chart

LLY Operating Margin (TTM) data by YCharts

Lilly hopes bigger margin will help blunt some of the pain from Cymbalta and Evista patent losses.

The company issued guidance calling for total 2014 sales of $19.2 billion to $19.8 billion in early January. But that guidance fell short of prior guidance in October for a minimum of $20 billion in sales. That has analysts ratcheting down their earnings outlook for 2014. Currently, the street expects Lilly's earnings to fall from $4.14 in 2013 to $2.78 per share this year.

That's got investors in wait-and-see mode. They're paying less for each dollar of Lilly's sales than they are for AstraZeneca, Novo, and Sanofi's sales. And despite the move up in margin, the drop off in earnings means Lilly's forward P/E ratio may be a bit rich at 18 times. That's higher than it's been in the past and much higher than Sanofi's 10 times multiple.

Despite the upcoming year's struggles, Lilly still has steady earners in its lung cancer drug Alimta, which had sales just shy of $2 billion in the first three quarters of 2013,  and Humalog, which saw sales grow 6% in the first nine months to nearly $1.9 billion. ADHD drug Strattera and cardiovascular drug Effient were the company's two fastest growing drugs in the third quarter, growing 19% and 14% year-over-year, respectively.

Fool-worthy final thoughts

Preserving earnings power through cost cutting and buybacks appears to be the focus for Lilly in 2014. The company is slashing its R&D budget by a billion dollars and announced plans in October for up to $5 billion in buybacks over time.

Lilly hopes that will help it transition to a new stage of growth as its pipeline matures. The company has 13 drugs in phase 3 and another 26 in phase 2, suggesting plenty of potential trial data to chew on over the coming year or two.

Drugs that investors should be on the lookout for news on this year include dulaglutide, a type 2 diabetes treatment, ramucirumab for gastric cancer, and necitumumab for non-small cell lung cancer. A bit further out, investors should watch ixekizumab. That drug has been promising in mid stage trials as a treatment for blockbuster autoimmune disease psoriasis. Lilly is studying the drug head-to-head with Amgen's Enbrel, a drug that racked up $8 billion in sales during 2012. If Lilly can successfully navigate 2014 it will emerge as a leaner and more profitable company, potentially setting it up to deliver much faster earnings growth in 2015 and beyond.

Here are 3 great companies for the long haul

As every savvy investor knows, Warren Buffett didn't make billions by betting on half-baked stocks. He isolated his best few ideas, bet big, and rode them to riches, hardly ever selling. You deserve the same. That's why our CEO, legendary investor Tom Gardner, has permitted us to reveal The Motley Fool's 3 Stocks to Own Forever. These picks are free today! Just click here now to uncover the three companies we love. 

Todd Campbell has no position in any stocks mentioned.  Todd owns E.B. Capital Markets, LLC.  E.B. Capital's clients may or may not have positions in the companies mentioned.  Todd also owns Gundalow Advisor's, LLC.  Gundalow's clients do not have positions in the companies mentioned.  The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers